Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001549595-26-000040
Filing Date
2026-07-09
Accepted
2026-07-09 16:12:07
Documents
69
Period of Report
2026-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-20260531.htm   iXBRL 10-Q 1488642
2 EX-10.2 nrix-20260531xxex102amendn.htm EX-10.2 63786
3 EX-31.1 nrix-20260531x10qxex311.htm EX-31.1 10676
4 EX-31.2 nrix-20260531x10qxex312.htm EX-31.2 10666
5 EX-32.1 nrix-20260531x10qxex321.htm EX-32.1 8281
  Complete submission text file 0001549595-26-000040.txt   6702163

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20260531.xsd EX-101.SCH 44985
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nrix-20260531_cal.xml EX-101.CAL 53255
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nrix-20260531_def.xml EX-101.DEF 222675
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20260531_lab.xml EX-101.LAB 586673
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20260531_pre.xml EX-101.PRE 394108
73 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20260531_htm.xml XML 714363
Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005
Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 261165801
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)